EUVIMEDEUVIMED entdecken
Crossref

Testosterone Replacement Therapy in Klinefelter Syndrome—Follow-up Study Associating Hemostasis and RNA Expression

Simon Chang iD, Jesper Just iD, Anne Skakkebæk iD, Emma B Johannsen iD, Jens Fedder iD, Claus H Gravholt iD, Anna-Marie B Münster iD

The Journal of Clinical Endocrinology & Metabolism · 15.03.2024 · 109 (4) · 978-991

DOI: 10.1210/clinem/dgad658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.11.2023. Verfasst von Simon Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Thrombosis Research, University Hospital of Southern Denmark, 6700 Esbjerg, Denmark. Hauptthemen laut MEDLINE: Klinefelter Syndrome, Hypogonadism, Thrombosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Familien Hede Nielsens Fond, Region Syddanmark, Karola Jørgensens Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Men with Klinefelter syndrome (KS) develop hypergonadotropic hypogonadism, are in need of testosterone replacement therapy (TRT), and present with a more than 4-fold increased risk of thrombosis. TRT in KS has the potential to modify thrombotic risk, but data are scarce.

Aim

To assess effects of 18 months of TRT on hemostasis in KS and identify genes associated with the prothrombotic phenotype.

Methods

Untreated and TRT-treated men with KS were included at baseline and matched to healthy controls. TRT was initiated in untreated KS and all groups were reassessed after 18 months of follow-up. Thrombin generation was evaluated with or without thrombomodulin, and fibrin clot lysis was evaluated by turbidity measurements. RNA expression was assessed in blood, fat, and muscle tissue of patients with TRT-treated KS and controls.

Results

Thrombin generation with thrombomodulin was slightly increased in untreated KS, but overall KS was not associated with a hypercoagulable state. KS presented with fibrinolytic impairment associated with higher body fat and higher levels of fibrinogen. Eighteen months of TRT in KS was associated with a reduction in body fat and fibrinogen, attenuating the prothrombotic profile. The expression of ENPP4 was higher in men with KS and served as a key player among a group of genes associated with impaired fibrinolysis.

Conclusion

KS is associated with a specific expression profile contributing to fibrinolytic impairment and increased thrombotic risk in the patients. TRT in patients with KS has the potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klinefelter SyndromeHypogonadismThrombosisMaleHumansFollow-Up StudiesThrombomodulinThrombinTestosteroneHemostasisFibrinogenRNA

Stichwörter der Autor:innen

Klinefelter syndromeblood coagulationfibrinolysisgenetic transcriptiontestosterone

Substanzen

ThrombomodulinThrombinTestosteroneFibrinogenRNA

Autor:innen und Institutionen

  • Unit for Thrombosis Research, University Hospital of Southern Denmark, 6700 Esbjerg, Denmark.
  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
  • Department of Clinical Genetics, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Centre of Andrology and Fertility Clinic, Odense University Hospital, 5000 Odense, Denmark.

ORCID-Profile: Simon Chang, Jesper Just, Anne Skakkebæk, Emma B Johannsen, Jens Fedder, Claus H Gravholt, Anna-Marie B Münster

Förderung

  • Familien Hede Nielsens Fond
  • Region Syddanmark
  • Karola Jørgensens Forskningsfond
  • A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
  • Novo Nordisk Foundation
  • Independent Research Fund Denmark
  • University of Southern Denmark
  • Aarhus University

Zitieren

APA

Chang, S., Just, J., Skakkebæk, A., Johannsen, E. B., Fedder, J., Gravholt, C. H., & Münster, A. B. (2024). Testosterone Replacement Therapy in Klinefelter Syndrome—Follow-up Study Associating Hemostasis and RNA Expression. The Journal of Clinical Endocrinology & Metabolism, 109(4), 978-991. https://doi.org/10.1210/clinem/dgad658

Vancouver

Chang S, Just J, Skakkebæk A, Johannsen EB, Fedder J, Gravholt CH, et al. Testosterone Replacement Therapy in Klinefelter Syndrome—Follow-up Study Associating Hemostasis and RNA Expression. The Journal of Clinical Endocrinology & Metabolism. 2024;109(4):978-991. doi:10.1210/clinem/dgad658

BibTeX
@article{Chang2024,
  author = {Chang, Simon and Just, Jesper and Skakkebæk, Anne and Johannsen, Emma B and Fedder, Jens and Gravholt, Claus H and Münster, Anna-Marie B},
  title = {Testosterone Replacement Therapy in Klinefelter Syndrome—Follow-up Study Associating Hemostasis and RNA Expression},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {4},
  pages = {978--991},
  doi = {10.1210/clinem/dgad658}
}
Kostenlos starten →